{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-004666","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-09-30T12:52:08+00:00","discovered_at":"2026-09-30T12:55:00.293899+00:00","generated_at":"2026-10-12T13:59:17.129684+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Silexion doses first patient in Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer","bullets":["First patient dosed at Tel Aviv Sourasky Medical Center (Ichilov) in Israel on September 30, 2026, Silexion announced.","Phase 2/3 trial evaluates SIL204 plus standard chemotherapy versus chemotherapy alone in unresectable Stage 3 LAPC with confirmed KRAS mutation.","Trial starts with a safety run-in of about 18 patients, then expands to a randomized cohort of about 166 patients.","SIL204 uses EUS-guided intratumoral delivery plus subcutaneous abdominal injections; additional Israel and Germany sites are expected to join.","CEO Ilan Hadar called the dosing a defining operational and clinical milestone for Silexion's lead RNAi program."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-004666","json":"https://secwatch.observer/filing/0001178913-26-004666.json","markdown":"https://secwatch.observer/filing/0001178913-26-004666.md","text":"https://secwatch.observer/filing/0001178913-26-004666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004666/0001178913-26-004666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004666/zk2636171.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:59:17.129684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}